Brief: Kronos Bio Announces First Patient Dosed With KB-0742 In An Expansion Cohort Focused On Platinum-Resistant High-Grade Serous Ovarian Cancer
23/07/2024 23:41
July 23 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO ANNOUNCES FIRST PATIENT DOSED WITH KB-0742 IN
AN
EXPANSION COHORT FOCUSED ON PLATINUM-RESISTANT HIGH-GRADE SEROUS
OVARIAN CANCER
* KRONOS BIO INC - EXPECTS TO PROVIDE AN EFFICACY UPDATE ON
THIS
EXPANSION COHORT IN 1H 2025 -
Source text for Eikon: ID:nGNX674b3G
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems